Brain

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed...

There Is No Place Like ALYZE: Why Health Experts Say Utah’s New Integrated Wellness Club Is in a Category of Its Own

Combining a CLIA-certified on-site laboratory, functional medicine, luxury fitness, precision medicine, full recovery services, and aesthetic wellness under one roof,...

Remepy Publishes New Evidence Showing its Hybrid Drug, Hybridopa™, Effect on Structural Connectivity in the Brain of Parkinson’s Patients Associated with Improved Clinical Outcome

New npj Parkinson's Disease publication, building on the previously reported Hybridopa™ Phase IIa results, demonstrates for the first time, that...

Oxford-Harrington Rare Disease Centre Strengthens Rare Childhood Cancer Programme Through Appointment of New Little Princess Trust Professor of Paediatric Oncology

Professor Isidro Cortés-Ciriano, an internationally recognised scientist with extensive experience in childhood cancer research, will accelerate Oxford-Harrington’s mission to translate...

Magnetic Resonance Imaging (MRI) Market to Reach USD 10.2 Billion by 2036 as AI Reconstruction and Low-Helium Systems Improve Imaging Efficiency | FMI

NEWARK, Del., June 30, 2026 /PRNewswire/ -- The global Magnetic Resonance Imaging (MRI) Market, according to Future Market Insights, is...

ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients

Patient enrollment has been completed; all enrolled patients remain aliveData presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual...

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time...

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102...

BioAdaptives Completes MyndSystem™ Platform with TruShield Certification of MyndRenew™, Securing Full WADA Compliance for Professional Athletes and Expanding Market Opportunity

Certification validates the complete day-and-night neuro-performance and repair system, positioning the company for broader adoption across elite sports and high-value...

error: Content is protected !!